Field & Main Bank’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.08K Hold
100
﹤0.01% 242
2025
Q4
$2.95K Hold
100
﹤0.01% 249
2025
Q3
$2.58K Hold
100
﹤0.01% 244
2025
Q2
$2.76K Hold
100
﹤0.01% 231
2025
Q1
$2.83K Hold
100
﹤0.01% 232
2024
Q4
$4.16K Hold
100
﹤0.01% 244
2024
Q3
$6.68K Hold
100
﹤0.01% 226
2024
Q2
$11.9K Hold
100
﹤0.01% 219
2024
Q1
$10.7K Hold
100
﹤0.01% 222
2023
Q4
$9.95K Hold
100
﹤0.01% 220
2023
Q3
$10.3K Hold
100
﹤0.01% 221
2023
Q2
$12.2K Hold
100
0.01% 222
2023
Q1
$15.4K Hold
100
0.01% 209
2022
Q4
$18K Hold
100
0.01% 207
2022
Q3
$12K Hold
100
0.01% 227
2022
Q2
$14K Hold
100
0.01% 236
2022
Q1
$17K Hold
100
0.01% 195
2021
Q4
$25K Buy
+100
New +$29.2K 0.01% 186

Other funds holding MRNA

Field & Main Bank's MRNA Position: Q1 2026 in Review

Field & Main Bank held its Moderna (MRNA) position steady in Q1 2026 at 100 shares worth $5.08K. The position accounts for ﹤0.01% of the portfolio, ranked #242.

Field & Main Bank first reported a position in MRNA in Q4 2021 and has held it in 18 quarters since. The position peaked at $25K in Q4 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Field & Main Bank held 100 shares of Moderna worth $5.08K as of Q1 2026.
  • Field & Main Bank left its Moderna share count unchanged in Q1 2026.
  • Moderna made up ﹤0.01% of Field & Main Bank's portfolio in Q1 2026, its #242 holding.
  • Field & Main Bank first reported a position in Moderna in Q4 2021 and has held it in 18 quarters since.
  • Field & Main Bank's Moderna position peaked at $25K in Q4 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Field & Main Bank's 13F filing for Q1 2026, filed 10 Apr 2026.